24 results about "Malignant transformation" patented technology

The invention belongs to the technical field of medical biological detection, and particularly relates to a gene marker combination for oral mucosa leukoplakia canceration risk and application of the gene marker combination. The gene marker combination is a combination of TP53, CASP8 and CYP2B6 genes and is obtained by screening through a WES technology, the predicted AUC of the gene marker combination reaches 0.813 (95% CI: 0.710-0.916), and the performance of the gene marker combination is remarkably superior to that of traditional pathological grading. Through Cox risk regression analysis, a high-risk group as an independent factor has significant statistical significance and is superior to traditional indexes such as age and diseased regions. The invention further provides an oral mucosa leukoplakia canceration risk prediction kit and prediction system derived from the gene combination.

The invention provides a mammary nodule malignant transformation risk prediction system and method, a terminal, a medium and a product. The system comprises a multi-source data acquisition module used for acquiring multi-source mammary gland related medical data of a target mammary nodule patient and preprocessing the multi-source mammary gland related medical data; the key prediction feature screening module is used for carrying out key feature screening on the preprocessed data to obtain mammary gland key prediction feature data; and the prediction module is used for inputting the breast key feature data into a pre-constructed breast nodule risk prediction model to obtain a corresponding breast nodule malignant transformation risk prediction result. According to the method, the related medical data of the multi-source mammary gland is integrated, and key feature screening and the mammary nodule risk prediction model are combined, so that the limitation of traditional single-dimensional evaluation is broken through, and early warning of malignant transformation of the mammary nodule is realized.

The invention discloses a marker combination for thyroid nodule risk assessment and application thereof. Based on large-sample multi-omics sequencing data, papillary thyroid carcinoma (PTC) and benign nodules are found to have a common epithelial spectrum origin, epithelial intermediate state cells (EICs) with malignant potential are found in the benign nodules, and typical molecular markers of the EICs are further identified to comprise ZCCHC12, CDLN1 and NPC2. The three genes participate in proliferation and differentiation of cells, the expression in PTC is remarkably up-regulated, and the malignant risk of the benign thyroid nodules can be evaluated by detecting the expression level of the markers in a biological sample. According to the method, a means for recognizing the high-risk benign nodules before malignant transformation occurs is provided for the first time, risk perspectiveness is achieved, and higher specificity and sensitivity are possibly achieved for recognizing the benign nodules with malignant potential.

The application provides a method for constructing an immortalized bovine nasopharyngeal tonsil epithelial cell line and application, and belongs to the technical field of cell engineering. The healthy yellow bovine nasopharyngeal tonsil is used as a material, and the primary epithelial cells are separated by enzyme digestion. The 3rd to 4th generation cells are taken, infected with SV40 T lentivirus (MOI=80), and screened by 1.5 μg / mL puromycin to obtain a stable immortalized cell line. The cell line is continuously passaged to the 50th generation and still stably expresses SV40LT protein and epithelial specific markers CD326, CD324 and KRT8, maintains a typical pavement stone-like morphology, normal proliferation and no malignant transformation. Infection experiments show that the cell is highly sensitive to FMDV, supports efficient replication, and the virus titer can reach 10 7.5 TCID 50 / mL. The application overcomes the defects of the existing immortalized bovine nasopharyngeal tonsil epithelial cell model, such as limited source, large batch difference, low sensitivity and poor persistence, and provides a stable and reliable in vitro model for the research of foot-and-mouth disease prevention and control related mechanisms, drug screening and vaccine development.

The invention provides a traditional Chinese medicine composition for improving acute and chronic abdominal inflammation and a preparation method thereof. The traditional Chinese medicine composition for improving acute and chronic abdominal inflammation can improve acute and chronic abdominal inflammation by optimizing the components of the formula and the content proportioning relationship among the components, has small side effects and quick response, and inhibits the process of transforming cells into malignant cells under the stimulation of chronic inflammation.

Embodiments described herein provide methods of determining a risk of progression of Barrett's esophagus in a subject, classifying Barrett's esophagus in a subject and detecting a field effect associated with malignant transformation of an esophagus of a subject suffering from Barrett's esophagus. The disclosure also provides kits for determining a risk of progression of Barrett's esophagus in a subject and classifying Barrett's esophagus in a subject.

The application discloses a method for improving the passaging times of a mammary epithelial cell line and application thereof, and belongs to the technical field of mammary epithelial cell lines. The application first finds that the exogenous fragment HS4-SAR fragment in the attachment area of the insulator-scaffold is connected with a p-Ef1a-SV40LT-Puro vector or a pEF1a-eGFP vector, and the transfection of commercial immortalized cell lines and primary cell lines can significantly improve the passaging times of the mammary epithelial cell lines, the cell morphology is still normal after 120 generations, the malignant transformation does not occur, the gene expression level does not decrease, and the immortalization is realized; the established goat mammary epithelial cell line still has the ability of synthesizing and secreting proteins; the method for improving the passaging times of the mammary epithelial cell line is simple and easy to operate, has a significant effect on the immortalized cell lines and the primary cell lines, and is expected to improve the stable passaging times of various mammary epithelial cell lines, and reduce the cell cost of related research.

This invention provides a method for constructing an esophageal cancer biomimetic organ model based on a complex hydrogel and its use, belonging to the field of medical biomimetic organ models. The biomimetic organ model is manufactured using a hydrogel as its framework. This invention constructs an in vitro biomimetic organ model of esophageal cancer with bioactivity, better simulates Pg infection in esophageal cancer patients, and finally introduces commonly used chemotherapy drugs to confirm the relationship between Pg and malignant changes in esophageal cancer, verify the drug screening function of the model, and compare it with clinical treatment effects.

The invention discloses a gastric cancer biomarker ENO3 and a detection reagent thereof, belongs to the technical field of biological medicines, and particularly relates to a detection reagent of a gastric cancer marker. The detection reagent comprises an upstream primer and a downstream primer of a gastric cancer marker, and modified immunomagnetic beads, the gastric cancer marker is enolase 3. The invention finds and verifies that the gastric cancer marker enolase 3 promotes malignant transformation of gastric cancer by promoting glycolysis of gastric cancer cells, activating a WNT / beta-catenin signal channel and up-regulating expression of matrix metalloproteinase at the same time; meanwhile, by optimizing an immunomagnetic bead structure targeting the marker, the capture efficiency of the marker on trace tumor cells in peripheral blood is improved, so that the signal intensity of subsequent marker detection is enhanced, and an important tool is provided for improving the positive detection rate of gastric cancer detection based on the peripheral blood.

The present application relates to a kind of eccDNA related to malignant transformation of hepatocellular carcinoma and its acquisition method and application, the nucleotide sequence of eccDNA is as shown in SEQ ID NO:1;The acquisition method and application of the eccDNA are also disclosed.The eccDNA obtained by the present application can exist stably in plasma and other body fluids, can be used for non-invasive or minimally invasive detection, can be used as early molecular marker of malignant transformation of hepatocellular carcinoma, and provides a new early warning idea of malignant transformation of hepatocellular carcinoma for the development of HBV-related liver cancer.

The invention belongs to the technical field of biology, and particularly relates to a PDCD10 protein molecule serving as a new target for early warning the final effect direction of arsenide-caused lung cancer and preventing the arsenide-caused lung cancer and application of the PDCD10 protein molecule. The invention discloses an application of a PDCD10 protein expression inhibitor in preparation of a medicine for preventing lung cancer caused by arsenide. After the PDCD10 is knocked down, the malignant effect of normal lung cells induced by the arsenide can be remarkably inhibited.

The invention discloses a construction method and application of an asbestos-caused lung carcinoma-in-situ animal model, and belongs to the technical field of biomedicine. The construction method comprises the following steps: firstly, carrying out multiple poisoning treatments on embryo fibroblasts by chrysotile, and then carrying out malignant transformation to obtain malignant transformed cells; a luciferase gene is introduced by utilizing lentivirus transfection; and injecting the successfully transfected malignant transformed cells into the lung of an experimental animal by adopting an intrapulmonary injection method, and feeding to obtain the lung carcinoma-in-situ animal model. The method creatively uses asbestos to induce malignant transformed embryo fibroblasts with cancerous characteristics to establish the lung in-situ cancer animal model, and has the advantages of short modeling period, high tumor formation rate, visualized cell transfer condition, capability of better reflecting the cancerous characteristics of asbestos and the like. The constructed model can be applied to clinical diagnosis and treatment research such as pathogenesis research and drug screening evaluation.

The invention relates to a metabolic biomarker for malignant transformation of chronic hepatitis B and application of the metabolic biomarker, and belongs to the technical field of biomedicine. The invention provides aldehyde oxidase 1 (AOX1) and its downstream metabolite pyridoxal phosphate (PLP) as metabolic biomarkers for chronic hepatitis B malignant transformation. Through metabonomics and transcriptomics analysis, a'first-rising and second-falling 'dynamic trajectory of PLP rising in a chronic hepatitis B stage and falling in a liver cancer stage is found, and HBx reduces the PLP level by inhibiting AOX1 expression. The marker can be used for preparing a detection reagent, a kit or an integrated device, and dynamic monitoring and early warning of the vicious transformation risk are realized by detecting the AOX1 / PLP level in samples such as serum. The marker has the advantages of being clear in mechanism, high in dynamic relevance, suitable for clinical transformation and the like, and a new means is provided for liver cancer risk monitoring of chronic hepatitis B patients.

The invention discloses a convenient-to-use hysteromyoma taking-out device for female reproductive system surgery, and relates to the technical field of medical instruments, in particular to a method for pushing away a bag through a displacement mechanism, expanding an opening of the bag after an annular bag is inflated through an inflation and deflation mechanism, and sleeving and wrapping myoma in an abdominal cavity through the opening of the bag. The myoma and the smashing assembly are wrapped together by the bag through the displacement mechanism, then gas in the annular bag is pumped out through the inflation and deflation mechanism, so that the opening of the bag is contracted, the annular bag drives the closing opening of the bag to be placed in the storage ring, and a closed smashing space is formed. Compared with an existing smashing protective sleeve which is prone to slipping, the bag is driven by the positioning rod to complete the myoma sleeving action, sealing after sleeving is completed by controlling the annular bag, slipping in an operation is avoided, it is guaranteed that the myoma smashing process is conducted in the bag, and the hidden danger that tissue debris generated by smashing is scattered to the abdominal cavity is avoided; the requirements of hysteromyoma diagnosis and treatment guidelines on malignant transformation risk prevention and control are met.

The application relates to application of a glutamine metabolism inhibitor V-9302 in preparation of a drug for treating diseases caused by cell malignant transformation of arsenic. The application is characterized in that the glutamine metabolism inhibitor V-9302 is used to inhibit the cell malignant transformation caused by arsenic, the malignant transformation phenotype of cells is reversed after the glutamine metabolism is inhibited, the cell doubling time is increased, the migration rate and the soft agar colony formation rate are reduced, and it is proved that the enhancement of the glutamine metabolism promotes the cell malignant transformation mediated by the synthesis of glutathione.

The invention provides an MDS malignant transformation risk assessment method based on machine learning and bone marrow cell morphology, and the method comprises the steps: S101, building a myelodysplastic syndrome (MDS) malignant transformation risk assessment model based on bone marrow morphology cell characteristics; s102, acquiring a bone marrow smear image of the MDS patient, identifying the bone marrow smear image, obtaining proportion data of the target type of bone marrow cells, and recording the proportion data as bone marrow cell type proportion data; s103, inputting the bone marrow cell type proportion data into an MDS malignant transformation risk assessment model, and calculating and outputting a risk assessment score of transformation from MDS to acute myelogenous leukemia (AML) of the patient; and S104, the patients are grouped according to the risk assessment scores, and a treatment scheme is recommended. The method has the advantages that the basic level is easy to obtain, the needed economic cost is low, calculation is convenient and the like, medical personnel can be assisted in optimizing treatment decisions, and the survival rate of high-risk patients is improved.

To provide a method for detecting a gene associated with malignant alteration of endodermal cysts.SOLUTION: The present invention provides a method for detecting a gene associated with malignant alteration of an endodermal cyst in a sample. The method includes a step of detecting, in a subject-derived sample, KRAS, and at least one selected from a group consisting of ARID1A, CDKN2A, CDKN2B, PTCH1, TSC1, PTEN, TP53, FLCN, BAP1, PTPRD, SUFU and CDKN1B.SELECTED DRAWING: None

The invention provides a biomarker for diagnosing bladder cancer and application of the biomarker, and by analyzing single-cell transcriptome data of normal bladder epithelial cells and bladder cancer cells, ZDHHC20 is found to be continuously increased in the process of transforming from the bladder epithelial cells to vicious cells, and is remarkably and highly expressed in human bladder cancer tissues. Functional studies show that overexpression of ZDHHC20 can significantly activate PI3K / AKT, Wnt / beta-catenin, cell cycle and other cancer-promoting signal channels, so that normal bladder epithelial cells obtain malignant growth ability independent of adherence. The results show that ZDHHC20 is an important molecule for driving the vicious transformation of bladder epithelial cells. The invention discloses a key effect of the ZDHHC20 in bladder cancer generation, and shows that the ZDHHC20 can be used as a bladder cancer diagnosis and treatment target.

This invention discloses a novel use of corilagin or a pharmaceutically acceptable salt thereof in the preparation of medicaments for the treatment and / or prevention of human papillomavirus (HPV) infection and related diseases. This invention is the first to discover and demonstrate that corilagin can downregulate the expression of HPV E6 and / or E7 oncogenic proteins, thereby inhibiting viral activity and blocking the malignant transformation process driven by the virus. Based on this original discovery, corilagin or a pharmaceutically acceptable salt thereof can be used to prepare medicaments or pharmaceutical compositions for the prevention and / or treatment of persistent HPV infection, reversal of cervical intraepithelial neoplasia, adjuvant therapy for cervical cancer, and treatment of other HPV-related diseases (including but not limited to oropharyngeal HPV infection, anal HPV infection, vulvar intraepithelial neoplasia, etc.), preferably prepared as a mucosal topical dosage form. This discovery provides a novel, structurally well-defined small molecule drug candidate for the prevention and treatment of HPV-related diseases.

The application discloses application of a fusion gene TVP23C-CDRT4 as an external chemical substance benzo[g,h,i]perylene exposure biomarker in evaluating exposure risk of cells or organisms in a benzo[g,h,i]perylene environment or risk of malignant transformation caused by benzo[g,h,i]perylene exposure. The application screens the fusion gene TVP23C-CDRT4 with a reduced expression level in a poisoned cell exposed to benzo[g,h,i]perylene by using a transcriptome technology, and experiments speculate that the gene is involved in a process of cell DNA damage caused by benzo[g,h,i]perylene exposure, so that the gene can be used as a benzo[g,h,i]perylene exposure biomarker. The application provides help for in-depth understanding of the role of the fusion gene in a mechanism of malignant transformation of cells or organisms caused by an external chemical substance, and has significant value in the fields of environmental health research and disease prevention.

The present application belongs to the technical field of traditional Chinese medicine, and relates to a traditional Chinese medicine composition for treating gastric mucosa metaplasia, a preparation method and application thereof. The traditional Chinese medicine composition comprises the following traditional Chinese medicine components in parts by weight: 9-18 parts of ginseng, 9-18 parts of white atractylodes, 9-18 parts of poria cocos, and 6-9 parts of licorice (stir-fried). The traditional Chinese medicine composition prepared by the present application can reduce damage to gastric mucosa glands, reduce oxidative stress damage, enhance antioxidant capacity, protect gastric mucosa glands, and prevent gastric mucosa metaplasia from further malignant transformation. The traditional Chinese medicine composition is safe and has no obvious toxic and side effects.

This invention relates to the application of hedera saponin A1 in the preparation of drugs for the prevention and / or treatment of seborrheic keratosis or its secondary lesions. Through molecular-level experiments, this invention verifies that hedera saponin A1 can directly bind to the AKT1 protein, inhibiting AKT1-induced upregulation of pro-apoptotic proteins, thereby initiating cell apoptosis. Compared with existing technologies, this invention is a non-invasive treatment, painless, non-invasive, and leaves no scars after healing. Furthermore, this invention has the dual efficacy of "treating seborrheic keratosis" and "chemopreventing malignant transformation." In addition, hedera saponin A1 has a significant killing effect on seborrheic keratosis lesion cells, exhibiting a killing effect on the epidermal layer of isolated seborrheic keratosis lesion tissue, but without inducing significant apoptosis in dermal cells.

The invention provides computer equipment for executing a multi-mode tongue picture-based pulmonary nodule intelligent evaluation method, which comprises a memory, a processor and a computer program, when the processor executes the program, the change values of the transparency percentage and the distribution density of the blood vessel wall are recognized according to the millimeter width value of sublingual vein expansion and the angle degree of branch tortuosity, the morphological data of the tongue image and the pulmonary nodule are extracted, and the correlation degree value of the blood vessel and the nodule in the pathological circulation is determined; performing position calibration on the sublingual vein image and the pulmonary nodule imaging data according to a correlation degree value of blood vessels and nodules in pathological circulation, and fusing pulmonary nodule blood supply intensity information to obtain a spatial position relation graph of sublingual vein and pulmonary nodule vasculopathy; the interaction between sublingual vein blood stasis expansion and the number of pulmonary nodule neovascularization is analyzed based on the spatial position relation graph of vasculopathy, tongue picture form change data in different periods are recognized, and the grading numerical value of the malignant transformation risk is judged.

The invention provides a complex for use in various therapeutic applications, and methods of treatment using the complex, or pharmaceutical compositions comprising the complex. The complex is particularly useful for treating malignant transformations, particularly cancer, especially where such transformations are found at a site distant from the site of administration of the complex, as well as for the treatment of metabolic-related conditions. The complex comprises a polypeptide having a sequence of a naturally occurring alpha-lactalbumin, or a functional variant thereof; or a peptide of up to 50 amino acids comprising an alpha-helical domain of said polypeptide; and a fatty acid or lipid or salt thereof.